



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

me

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/770,668	02/02/2004	Susan C. Wright	115-000420US	2158

22798 7590 04/09/2007
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P O BOX 458
ALAMEDA, CA 94501

EXAMINER

FETTEROLF, BRANDON J

ART UNIT	PAPER NUMBER
----------	--------------

1642

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	04/09/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No. .

10/770,668

Applicant(s)

WRIGHT ET AL.

Examiner

Brandon J. Fetterolf, PhD

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on 16 January 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-19 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>9/20/2006</u> | 6) <input type="checkbox"/> Other: _____ |

Response to the Amendment

The Amendment filed on 1/16/2007 in response to the previous Non-Final Office Action (7/12/2006) is acknowledged and has been entered.

Claims 1-19 are currently pending and under consideration.

Information Disclosure Statement

The Information Disclosure Statement filed on 9/20/2006 is acknowledged. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. A signed copy of the IDS is attached hereto.

Rejections Withdrawn:

The rejection of Claims 1-2 under 35 U.S.C. 102(b) as being anticipated by Bandman et al. (US 6,274,138, 2001) has been withdrawn in view of Applicants arguments.

New Rejections upon Reconsideration:

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-5, 8 and 17 are rejected under 35 U.S.C. 102(b) as being anticipated by Tang et al. (WO 01/66689 A2, 2001, *of record*).

Tang et al. teach a composition comprising an isolated amino acid sequence, which has at least 99.8% sequence identity to the claimed SEQ ID NO: 4, comprising the instantly claimed amino acid sequence of SEQ ID NO: 6 and/or 7 and having SEQ ID NO: 4 (SEQ ID NO: 233 of WO publication, see below sequence comparison). With respect to the amino acid sequence, the WO publication teaches that the amino acids include, but are not

Art Unit: 1642

limited to, both full length (comprising a signal sequence) and mature forms (without a signal sequence) (page 28, lines 19-20). Moreover, Tang et al. teach that the polypeptides may be operably linked to a targeting moiety such as an antibody which binds to a cell molecule (page 32, lines 1-14 and line 34 to page 33, line 25). For example, the WO publication teaches that the polypeptides may be operably linked to an antibody which specifically binds a target on pancreatic cells. In the instant case, the transitional phrase "comprises", which is synonymous with "including," "containing," or "characterized by," recited in the current claims is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. See, e.g., > Mars Inc. v. H.J. Heinz Co., 377 F.3d 1369, 1376, 71 USPQ2d 1837, 1843 (Fed. Cir. 2004) ("like the term comprising,' the terms containing' and mixture' are open-ended.").< Invitrogen Corp. v. Biocrest Mfg., L.P., 327 F.3d 1364, 1368, 66 USPQ2d 1631, 1634 (Fed. Cir. 2003) Genentech, Inc. v. Chiron Corp., 112 F.3d 495, 501, 42 USPQ2d 1608, 1613 (Fed. Cir. 1997) ("Comprising" is a term of art used in claim language which means that the named elements are essential, but other elements may be added and still form a construct within the scope of the claim.). Thus, in view of the transitional phrase, Tang et al. teach a composition comprising a portion of SEQ ID NO: 4, wherein the portion comprises SEQ ID NO: 6 or SEQ ID NO: 7. Moreover, although Tang et al. does not specifically teach that the polypeptide has activity chosen from DNA nuclease activity and cell killing activity, the claims are drawn to the product *per se* and inherently, such a polypeptide have activity chosen from DNA nuclease activity and cell killing activity. Thus, the claimed peptide appears to be the same as the prior art. The office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See In re Best 562F.2d 1252, 195 USPQ 430 (CCPA 1977) and Ex parte Gray 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989).

Comparison between Tang's SEQ I DNO: 233 and claimed SEQ ID NO: 6
Novel human secretory protein, Seq ID No 233.
WO200166689-A2.

Tang YT, Liu C, Asundi V, Xu C, Wehrman T, Ren F, Ma Y, Zhou P;
Zhao QA, Yang Y, Drmanac RT, Zhang J, Chen R, Xue AJ, Wang J;

Art Unit: 1642

1 KAKAGAGSATLSMAYAGARFVFSLV DAMNGKEGVVECSFVKSQETECTYFSTPLLLGKKG 60
|||||
239 KAKAGAGSATLSMAYAGARFVFSLV DAMNGKEGVVECSFVKSQETECTYFSTPLLLGKKG 298

61 IEKNLGIGKVSS 72
|||||
299 IEKNLGIGKVSS 310

Comparison between Tang's SEQ I DNO: 233 and claimed SEQ ID NO: 7
Novel human secretory protein, Seq ID No 233.
WO200166689-A2.

Tang YT, Liu C, Asundi V, Xu C, Wehrman T, Ren F, Ma Y, Zhou P;
Zhao QA, Yang Y, Drmanac RT, Zhang J, Chen R, Xue AJ, Wang J;
1 KAKAGAGSATLSMAYAGARFVFSLV DAMNGKEGVVECSFVKSQETECTYFSTPLLLGKKG 60
|||||
239 KAKAGAGSATLSMAYAGARFVFSLV DAMNGKEGVVECSFVKSQETECTYFSTPLLLGKKG 298

61 IEKNLGIGKVSSFEEKMISDAIPELKASIKKGEDFVKTLK 100
|||||
299 IEKNLGIGKVSSFEEKMISDAIPELKASIKKGEDFVKTLK 338

Comparison between Tang's SEQ I DNO: 233 and claimed SEQ ID NO: 4
Novel human secretory protein, Seq ID No 233.
WO200166689-A2.

Tang YT, Liu C, Asundi V, Xu C, Wehrman T, Ren F, Ma Y, Zhou P;
Zhao QA, Yang Y, Drmanac RT, Zhang J, Chen R, Xue AJ, Wang J;

Query Match 99.8%; Score 1706; DB 4; Length 338;
Best Local Similarity 99.7%; Pred. No. 9.7e-168;
Matches 337; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1 MLSALARPASAAARRSFSTSAQNNKAVAVLGASGGIGQPLSLLLKNSPLVSRLTLYDIAH 60
|||||
1 MLSALARPVSAARRSFSTSAQNNKAVAVLGASGGIGQPLSLLLKNSPLVSRLTLYDIAH 60

61 TPGVAADLSHIETKAAVKGYLGPEQLPDCLKGCDVVIPAGVPRKPGMTRDDL FNTNATI 120
|||||
61 TPGVAADLSHIETKAAVKGYLGPEQLPDCLKGCDVVIPAGVPRKPGMTRDDL FNTNATI 120

121 VATLTAACAQHCPEAMICVIANPVNSTIPITA EVFKKHGVYNPNKIFGVTTLDIVRANTF 180
|||||
121 VATLTAACAQHCPEAMICVIANPVNSTIPITA EVFKKHGVYNPNKIFGVTTLDIVRANTF 180

181 VAELKGLDPARVNPVIGGHAGKTIIP LISQCTPKVD FPDQDLTALTGRIQEAGTEVVKA 240
|||||
181 VAELKGLDPARVNPVIGGHAGKTIIP LISQCTPKVD FPDQDLTALTGRIQEAGTEVVKA 240

241 KAGAGSATLSMAYAGARFVFSLV DAMNGKEGVVECSFVKSQETECTYFSTPLLLGKKGIE 300
|||||
241 KAGAGSATLSMAYAGARFVFSLV DAMNGKEGVVECSFVKSQETECTYFSTPLLLGKKGIE 300

301 KNLGIGKVSSFEEKMISDAIPELKASIKKGEDFVKTLK 338
|||||
301 KNLGIGKVSSFEEKMISDAIPELKASIKKGEDFVKTLK 338

Note: In order to Expedite prosecution, the Examiner would like to address Applicants arguments pertaining to the previous rejection under 102(b) as being anticipated by Tang. As a preliminary matter, Applicants assert that only page 1 of Tang et al. was provided to Applicants; and further, after reviewing Tang et al. on line, it appears that no sequences are provided in the published reference, making the relevance of Tang et al. rather unclear. Applicants further submit that certain of the priority documents of Tang et al. include over 600 hundred pages worth of sequence listings. Thus, Applicants take the Examiner's argument to be that one of these many thousands of sequences (see also Tang et al. claim 1) includes an MDH sequence that is the same as SEQ ID NO: 4 of the subject application. Assuming, arguendo, that the Actions statements regarding the presence of an MDH sequence in Tang are correct, Applicants argue that the reference still completely fails to disclose a polypeptide wit the claimed activity. For example, Applicants assert that the Action argues that Tang teaches a mature form of MDH coupled to various targeting moieties. However, Applicants argue that the full length mature MDH *does not have nuclease activation properties or cell killing activity* and no fragment of MDH that possess these properties are taught by Tang or alleged in this action. As such, Applicants assert that the references, therefore, completely fails to meet the limitations in the claims.

These arguments have been carefully considered, but are not found persuasive.

Regarding the preliminary matter submitted by Applicants, the Examiner apologizes that only page 1 of Tang et al was provided to Applicants and believes that this may have been a problem with the mailing department at the office because it appears that Tang et al. was scanned into the system. With regards to the publication of the sequences, the Examiner acknowledges that the sequences were not published along with publication of WO 01/66689. However, the Examiner recognizes that the sequence listing part of the description was published separately in election form and was made available to the public upon request the International Bureau (see page 1, 2nd column, Published: of the WO publication). As such, Tang et al. meets the requirements of 35 U.S.C. 102(b) and is therefore relevant. Moreover, the Examiner has attached an amino acid sequence comparison between the claimed SEQ ID NO: 4 and Tang et al. SEQ ID NO: 233 which reveals that Tang et al.'s SEQ ID NO: 233 has 99.8% sequence identity to SEQ ID NO: 4.

Art Unit: 1642

As such, Applicants arguments pertaining to Tang et al.'s peptide not having cell killing activity because SEQ ID NO: 4 simply does not have this activity are moot. As stated above, although Tang et al. does not specifically teach that the polypeptide has activity chosen from DNA nuclease activity and cell killing activity, the claims are drawn to the product *per se* and inherently, such a polypeptide comprising SEQ ID NO: 6 or 7 as claimed would have this functional limitation. Thus, the claimed peptide appears to be the same as the prior art. The office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See *In re Best* 562F.2d 1252, 195 USPQ 430 (CCPA 1977) and *Ex parte Gray* 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 9-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tang et al. (WO 01/66689, 2001, *of record*) in view of Wang et al. (Cancer Research 1991; 51: 3353-3355, *of record*).

Art Unit: 1642

Tang et al. teach, as applied to claims 1-5, 8 and 17 above, a composition comprising an isolated amino acid sequence, which has at least 99.8% sequence identity to the claimed SEQ ID NO: 4, comprising the instantly claimed amino acid sequence of SEQ ID NO: 6 and/or 7 and having SEQ ID NO: 4 (SEQ ID NO: 233 of WO publication, see below sequence comparison). With respect to the amino acid sequence, the WO publication teaches that the amino acids include, but are not limited to, both full length (comprising a signal sequence) and mature forms (without a signal sequence) (page 28, lines 19-20). Moreover, Tang et al. teach that the polypeptides may be operably linked to a targeting moiety such as an antibody which binds to a cell molecule, wherein the targeting moiety increases the biological activity of the polypeptide (page 32, lines 1-14 and line 34 to page 33, line 25). In addition, the WO document teaches that the polypeptide is useful for the treatment of cancers including, but not limited to, liver cancer (page 53, lines 5-29).

Tang et al. do not explicitly teach that the antibody binds to liver cancer cells, wherein the antibody is Hepama-1.

Wang et al. teach a Hepama-1 antibody toxin conjugate. Specifically, the reference teaches that the hepatoma cytotoxicity of the conjugate was 500-fold higher as compared to the free toxin.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was to combine the teachings of the references so as to attach the polypeptide as taught by Tang et al. with an antibody such as Hepama-1 in view of the Wang et al. One would have been motivated to do so because Wang et al. teaches that the hepatoma cytotoxicity of the conjugate was 500-fold higher as compared to the free toxin. Thus, one of ordinary skill in the art would have a reasonable expectation of success that by attaching the polypeptide as taught by Tang et al. with an antibody such as Hepama-1 in view of the Wang et al, one would achieve a method for specific delivery and targeting of the polypeptide for the treatment of liver cancer.

Note: In order to expedite prosecution, the Examiner would like to address Applicants arguments pertaining to the previous rejection under 35 U.S.C. 103(a) as being unpatentable over Tang et al. (WO 01/66689, 2001) in view of Wang et al. (Cancer Research 1991; 51: 3353-3355). In response to this previous rejection, Applicants assert that nothing in the

Art Unit: 1642

combination of references teaches the basic limitations of the claims. For example, Applicants assert that Tang et al. teach the mature MDH polypeptide which does not have DNA fragmentation/cell-killing activity and Wang teaches nothing regarding an MDH polypeptide or fragment thereof. Moreover, Applicants assert that Tang et al. does not teach anything at all regarding anti-activity of any MDH polypeptide or fragment, but at best list several thousand nucleic acid and peptide sequences then alleges that some of the sequences “may” have any of a variety of activities listed on page 39-60 of Tang. However, Applicants assert that this is not a meaningful teaching to one of skill regarding any specific polypeptide activity for any specific polypeptide. Moreover, Applicants assert that it could just as easily be stated that somewhere in Genbank there may or may not be a gene that is involved with one or more medical disorders found in Harrison’s guide to Internal Medicine. Yet, Applicants assert that this would not invalidate a latter invention that relies on the discovery of a specific association between a gene and a disease, because, while the statement of Genbank might include some disease related genes is true it is meaningless in any practical sense.

These arguments have been carefully considered, but are not found persuasive.

Applicants arguments pertaining to Tang et al.’s peptide not having cell killing activity because SEQ ID NO: 4 simply does not have this activity have been discussed above and are incorporated herein. Regarding Applicants assertion that Tang et al. does not teach anything regarding the anticancer activity of any MDH polypeptide or fragment thereof, the Examiner acknowledges that Tang et al. does not explicitly teach the activity of any MDH polypeptide. However, the Examiner recognizes that Tang et al. clearly teaches that the polypeptides, including SEQ ID NO: 233, are useful for the treatment of cancers including, but not limited to, liver cancer (page 53, lines 5-29). As such, even if a reference discloses an inoperative device, it is prior art for all that it teaches. (emphasis added) Beckman Instruments v. LKB Produkter AB, 892 F.2d 1547, 1551, 13 USPQ2d 1301, 1304 (Fed. Cir. 1989). Therefore, “a non-enabling reference may qualify as prior art for the purpose of determining obviousness under 35 U.S.C. 103.” Symbol Techs. Inc. v. Opticon Inc., 935 F.2d 1569, 1578, 19 USPQ2d 1241, 1247 (Fed. Cir. 1991).

Claims 6-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tang et al. (WO 01/66689, 2001, *of record*) in view of Sherman et al. (2002/0022027, 2002, *of record*).

Tang et al. teach, as applied to claims 1-5, 8 and 17 above, a composition comprising an isolated amino acid sequence, which has at least 99.8% sequence identity to the claimed SEQ ID NO: 4, comprising the instantly claimed amino acid sequence of SEQ ID NO: 6 and/or 7 and having SEQ ID NO: 4 (SEQ ID NO: 233 of WO publication, see below sequence comparison). With respect to the amino acid sequence, the WO publication teaches that the amino acids include, but are not limited to, both full length (comprising a signal sequence) and mature forms (without a signal sequence) (page 28, lines 19-20). Moreover, Tang et al. teach that the polypeptides may be operably linked to a targeting moiety such as an antibody which binds to a cell molecule, wherein the targeting moiety increases the biological activity of the polypeptide (page 32, lines 1-14 and line 34 to page 33, line 25). In addition, the WO document teaches that the polypeptide is useful for the treatment of cancers including, but not limited to, liver cancer (page 53, lines 5-29).

Tang et al. do not explicitly teach that the polypeptide-antibody conjugate further comprises a cell internalization peptide and/or nuclear localization peptide.

Sherman et al. teach a composition comprising a Vpr polypeptide conjugated to a therapeutic molecule (ab). With regards to the Vpr peptide, the publication teaches that Vpr contains at least two nuclear localization signals and is capable of delivering molecules to the cell nucleus (page 1, 2nd column, paragraph 0006). With regards to the therapeutic molecule, Sherman et al. teach that the therapeutic molecules include, but are not limited to, polypeptides, polynucleotides and toxins (page 1, 1st column, paragraph 0007). Moreover, the publication teaches a method of killing a target cell and/or inhibiting cell proliferation or a target cell comprising administering a Vpr peptide conjugate or Vpr alone, wherein the Vpr conjugate is delivered into a cell and said cell is a cancer cell (abstract; page 1, 2nd column, paragraph 0008 and page 2, 1st column, paragraph 0010).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was to combine the teachings of the references so as to further attach a cell internalization/ nuclear localization peptide to the antibody-polypeptide conjugate as taught by Tang et al. in view of the Sherman et al.. One would have been motivated to do so because Sherman et al. teach that Vpr polypeptides conjugated to therapeutic molecules

Art Unit: 1642

allows for the selective delivery of the therapeutic molecule within the cell, wherein the therapeutic molecule is released from the Vpr by protease cleavage of the Vpr conjugate. Thus, one of ordinary skill in the art would have a reasonable expectation of success that by administering an antibody-polypeptide conjugate as taught by Tang et al. in view of Wang et al. which further comprises a cell internalization/ nuclear localization peptide, one would achieve a method for specific delivery and targeting the polypeptide for the treatment of cancer.

Secondly, each of the agents, e.g., the polypeptide and a Vpr polypeptide, have been individually taught in the prior art as being useful for the treatment of cancer. As such, the strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent, that some advantage or expected beneficial result would have been produced by their combination. In re Sernaker, 702 F.2d 989, 994-95, 217 USPQ 1, 5-6 (Fed. Cir. 1983).

Note: In order to Expedite prosecution, the Examiner would like to address Applicants arguments pertaining to the previous rejection under 35 U.S.C. 103(a) as being unpatentable over Tang et al. (WO 01/66689, 2001) in view of Sherman et al. (2002/0022027, 2002). In response to this previous rejection, Applicants that the rejections present similar issues to those which have been previously discussed above.

These arguments have been carefully considered, but are not found persuasive for the reasons set forth above.

Therefore, NO claim is allowed


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brandon J. Fetterolf, PhD whose telephone number is (571)-272-2919. The examiner can normally be reached on Monday through Friday from 7:30 to 4:30.

Art Unit: 1642

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Brandon J Fetterolf, PhD
Patent Examiner
Art Unit 1642

A handwritten signature in black ink, appearing to read "Brandon Fetterolf, PhD", with a large, sweeping flourish extending from the end of the signature.

BF